[1]王政强,韩锋博.肝癌切除术联合肝动脉化疗栓塞术治疗中晚期肝癌疗效观察[J].新乡医学院学报,2021,38(10):957-960.[doi:10.7683/xxyxyxb.2021.10.012]
　WANG Zhengqiang,HAN Fengbo.Effect of hepatectomy combined with transcatheter hepatic arterial chemoembolization in the treatment of middle-advanced liver cancer[J].Journal of Xinxiang Medical University,2021,38(10):957-960.[doi:10.7683/xxyxyxb.2021.10.012]
点击复制

肝癌切除术联合肝动脉化疗栓塞术治疗中晚期肝癌疗效观察
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
38
期数:
2021年10
页码:
957-960
栏目:
临床研究
出版日期:
2021-10-05

文章信息/Info

Title:
Effect of hepatectomy combined with transcatheter hepatic arterial chemoembolization in the treatment of middle-advanced liver cancer
作者:
王政强1; 韩锋博2
（1.长安医院普外科，陕西　西安　710018；2.长安医院血管外科，陕西　西安　710018）
Author(s):
WANG Zhengqiang1; HAN Fengbo2
(1.Department of General Surgery,Chang′an Hospital,Xi′an 710018,Shaanxi Province,China;2.Department of Vascular Surgery,Chang′an Hospital,Xi′an 710018,Shaanxi Province,China)
关键词:
肝癌; 肝癌切除术; 肝动脉化疗栓塞术
Keywords:
liver cancer; hepatectomy; transcatheter hepatic arterial chemoembolization
分类号:
R735.7
DOI:
10.7683/xxyxyxb.2021.10.012
文献标志码:
A
摘要:
目的　探讨肝癌切除术联合肝动脉化疗栓塞术（TACE）治疗中晚期肝癌的临床疗效。方法　选择2015年1月至2018年1月长安医院收治的126例中晚期肝癌患者为研究对象，根据治疗方式将患者分为观察组（n=70）和对照组（n=56），对照组患者行肝癌切除术，观察组患者行肝癌切除术联合TACE。对2组患者治疗前及治疗后1个月血清甲胎蛋白（AFP）、血管内皮生长因子（VEGF ）水平进行比较；治疗后2个月采用世界卫生组织实体瘤客观疗效评价标准评估2组患者的近期临床疗效；采用Kaplan-Meier法分析中晚期肝癌患者生存情况。结果　治疗前2组患者血清AFP、VEGF水平比较差异无统计学意义（P＞0.05），2组患者治疗后1个月血清AFP、VEGF水平显著低于治疗前（P＜0.05）；治疗后1个月，观察组患者血清AFP、VEGF水平显著低于对照组（P＜0.05）。观察组患者完全缓解率和总有效率分别为34.29%（24/70）、85.71%（60/70），对照组患者完全缓解率和总有效率分别为17.86%（10/56）、69.64%（39/56），观察组患者完全缓解率和总有效率均显著高于对照组（χ2=4.262、4.773，P＜0.05）。Kaplan-Meier生存分析显示，观察组和对照组患者术后2 a总生存率分别为48.57%（34/70）、35.71%（20/56），观察组患者术后2 a总生存率显著高于对照组（χ2=4.005，P＜0.05）。结论　肝癌切除术联合TACE可以提高中晚期肝癌患者的近期治疗效果和生存率。
Abstract:
Objective　To investigate the clinical efficacy of hepatectomy combined with transcatheter hepatic arterial chemoembolization (TACE) in the treatment of middle-advanced liver cancer.Methods　A total of 126 patients with middle-advanced liver cancer admitted to Chang′an Hospital from January 2015 to January 2018 were selected as the research subjects,and the patients were divided into observation group (n=70) and control group (n=56) according to the treatment method.The patients in the control group underwent hepatectomy,while the patients in the observation group underwent hepatectomy combined with TACE.The levels of serum alpha fetoprotein (AFP) and vascular endothelial growth factor (VEGF) were compared between the two groups before and one month after treatment.Two months after treatment,the short-term clinical efficacy of the patients in the two groups was evaluated by the Response Evaluation Criteria in Solid Tumors of World Health Organization.The survival of patients with middle-advanced liver cancer was analyzed by Kaplan-Meier method.Results　There was no significant difference in the levels of serum AFP and VEGF between the two groups before treatment (P>0.05).The levels of serum AFP and VEGF at one month after treatment were significantly lower than those before treatment in the two groups (P＜0.05).The levels of serum AFP and VEGF in the observation group were significantly lower than those in the control group at one month after treatment (P＜0.05).The complete remission rate and total effective rate in the observation group were 34.29% (24/70) and 85.71% (60/70),respectively;and the complete remission rate and total effective rate in the control group were 17.86% (10/56) and 69.64% (39/56),respectively.The complete remission rate and total effective rate in the observation group were significantly higher than those in the control group (χ2=4.262,4.773;P＜0.05).Kaplan Meier survival analysis showed that the two-year overall survival rate of patients in the observation group and the control group was 48.57% (34/70) and 35.71% (20/56),respectively.The two-year overall survival rate of patients in the observation group was significantly higher than that in the control group (χ2=4.005,P＜0.05).Conclusion　The hepatectomy combined with TACE can improve the short-term treatment effect and survival rate of patients with middle-advanced liver cancer.

参考文献/References:

［1］　BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2018,68(6):394-424.
［2］　王琳，童章隆，叶园，等.HBx基因与乙型肝炎病毒相关性肝癌的关系［J］.中国老年学杂志，2018，38（17）：4319-4321.
［3］　TSAI K Y,CHEN H A,WANG W Y,et al.Long-term and short-term surgical outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma:might laparoscopic approach be better in early HCC［J］.Surg Endosc,2019,33(4):1131-1139.
［4］　王云检，张珉，张玲，等.原发性肝癌非根治性切除术中肝断面处理方法研究［J］.新乡医学院学报，2019，36（8）732-735，739.
［5］　SUN J J,WANG K,ZHANG C Z,et al.Postoperative adjuvant transcatheter arterial chemoembolization after R0 hepatectomy improves outcomes of patients who have hepatocellular carcinoma with microvascular invasion［J］.Ann Surg Oncol,2016,23(4):1344-1351.
［6］　WANG Y Y,WANG L J,XU D,et al.Postoperative adjuvant transcatheter arterial chemoembolization should be considered selectively in patients who have hepatocellular carcinoma with microvascular invasion［J］.HPB(Oxford),2019,21(4):425-433.
［7］　赵剑，吴涯昆．肝切除术联合预防性TACE治疗原发性肝癌［J］.肝胆外科杂志，2018，26（5）：360-363．
［8］　孙志民，徐永建，华小斌，等．原发性肝细胞癌根治术后行预防性TACE的应用价值及复发危险因素分析［J］.中国现代普通外科进展，2021，24（6）：474-477．
［9］　叶胜龙，秦叔逵，吴孟超，等.原发性肝癌规范化诊断专家共识［J］.中华肝脏病杂志，2009，17（6）：295-304.
［10］　WORLD HEALTH ORGANIZATION.WHO handbook for reporting results of cancer treatment［R］.Geneva:World Health Organization,1979.
［11］　JUNG S M,KIM J M,CHOI G S,et al.Characteristics of early recurrence after curative liver resection for solitary hepatocellular carcinoma［J］.J Gastrointest Surg,2019,23(2):304-311.
［12］　BURREL M,REIG M,FORNER A,et al.Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolization (TACE) using drug eluting beads:implications for clinical practice and trial design［J］.J Hepatol,2012,56(6):1330-1335.
［13］　徐国斌，易广新，熊斌，等.原发性肝癌术后早期肝内复发转移36例的介入治疗［J］.介入放射学杂志，2013，22（4）：325-328.
［14］　魏复群，罗柳平，梁东，等．Ki-67表达与原发性肝癌根治性切除术后行预防性肝动脉化疗栓塞患者预后的关系［J］.中国普通外科杂志，2019，28（7）：825-832.
［15］　杨针，汪建林，尚润泽，等.术前血清甲胎蛋白水平与肝细胞癌术后患者早期复发的相关性分析［J］.中华肝胆外科杂志，2018，24（3）：179-183.
［16］　MATSUI D,NAGAI H,MUKOZU T,et al.VEGF in patients with advanced hepatocellular carcinoma receiving intra-arterial chemotherapy［J］.Anticancer Res,2015,35(4):2205-2210.
［17］　张玉扬，赵林，董奇观.原发性肝癌切除术后行肝动脉化疗栓塞效果及对患者血清AFP、CA19-9水平的影响［J］.山东医药，2018，58（2）：52-54.
［18］　丛文铭，吴孟超.肝癌术后复发的诊断及治疗［J］.中国实用外科杂志，2012，32（10）：809-811.

相似文献/References:

[1]王克霞,张荣波,唐小龙,等.肝细胞性肝癌与乙型肝炎病毒感染相关性的研究[J].新乡医学院学报,1997,14(03):281.
[2]杨瑞民,张凯,李玉侠,等.巨块型肝癌肝动脉栓塞后无水酒精注射疗效观察[J].新乡医学院学报,1997,14(04):382.
[3]甄艳华,杨利霞.肝癌患者肝动脉血流动力学的彩色多普勒研究[J].新乡医学院学报,2008,25(01):062.
[4]沈洁,阮健,郑航,等.ZD6474对肝癌HepG2细胞的抑制作用[J].新乡医学院学报,2010,27(03):234.
[5]黄长山,余伟,王云检,等.外科Apgar评分在肝癌术后并发症预测中的应用 TitleFilter('chTitle');[J].新乡医学院学报,2010,27(04):365.
[6]孙春伟,吴广银.哺乳动物雷帕霉素靶蛋白对肝癌细胞系Hep3B中侧群细胞的影响[J].新乡医学院学报,2011,28(03):307.
[7]王　雷１,王煜霞２,薛会朝１. 肝癌患者肿瘤坏死因子α和白细胞介素８水平变化及其与临床病理特征的关系[J].新乡医学院学报,2015,32(08):735.
[8]罗羽田,李世朋,徐红伟,等.铁死亡在肝癌中的调控机制及作用研究进展[J].新乡医学院学报,2021,38(1):091.[doi:10.7683/xxyxyxb.2021.01.020]
[9]王云检,张　珉,张　玲,等.原发性肝癌非根治性切除术中肝断面处理方法研究[J].新乡医学院学报,2019,36(8):732.[doi:10.7683/xxyxyxb.2019.08.007]
　WANG Yun-jian,ZHANG Min,ZHANG Ling,et al.Study on the treatment of residue liver in non-radical hepatectomy of primary liver cancer[J].Journal of Xinxiang Medical University,2019,36(10):732.[doi:10.7683/xxyxyxb.2019.08.007]
[10]李　妍,朱绍辉,张　彬.肝癌患者肝切除术后感染性并发症的相关危险因素分析[J].新乡医学院学报,2016,33(9):767.[doi:10.7683/xxyxyxb.2016.09.007]
　LI Yan,ZHU Shao-hui,ZHANG Bin.Analysis of the risk factors for infectious complications in patients with hepatocellular carcinoma after hepatectomy[J].Journal of Xinxiang Medical University,2016,33(10):767.[doi:10.7683/xxyxyxb.2016.09.007]

更新日期/Last Update: 2021-10-05